Original articleThe Neovascular Age-Related Macular Degeneration Database: Multicenter Study of 92 976 Ranibizumab Injections: Report 1: Visual Acuity
Cited by (0)
∗Supplemental material is available at www.aaojournal.org.
Financial Disclosure(s): The author(s) have made the following disclosure(s):
Robert L. Johnston: Employee – Medisoft Limited.
Supported in part by an unrestricted grant from Novartis Pharmaceuticals UK Limited, Frimley, UK. No member or affiliate of Novartis had any input into data analysis, interpretation of the data, or writing the manuscript. This research received a proportion of its funding from the Department of Health's NIHR Biomedical Research Centre for Ophthalmology at Moorfields Eye Hospital and UCL Institute of Ophthalmology. The views expressed in the publication are those of the authors and not necessarily those of the Department of Health.
Correspondence: Adnan Tufail, MD, FRCOphth, Moorfields Eye Hospital NHS Trust, 162 City Road, London EC1V 2PD, United Kingdom. E-mail: [email protected].
- ∗
A complete list of members of the UK Age-Related Macular Degeneration EMR Users Group is available at www.aaojournal.org.Writing Committee for the UK Age-Related Macular Degeneration EMR Users Group: Adnan Tufail, MD, FRCOphth; Wen Xing, MSc; Robert Johnston, FRCOphth; Toks Akerele, MD, FRCOphth; Martin McKibbin, FRCOphth; Louise Downey, MBChB, FRCOphth; Salim Natha, MBChB, FRCOphth; Usha Chakravarthy, MD, PhD; Clare Bailey, MD, FRCOphth; Rehna Khan, MB, ChB; Richard Antcliff, FRCOphth; Stewart Armstrong, FRCOphth; Atul Varma, MSCOphth; Vineeth Kumar, FRCSEd(Ophth); Marie Tsaloumas, MBBS, FRCOphth; Kaveri Mandal, FRCSEd(Ophth); and Catey Bunce, DSc.